Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.
Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candid
AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfro
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl